Burning mouth syndrome responsive to pramipexol.
Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings.
Stuginski-Barbosa
J
J
The Department of Neurology, School of Medicine at Ribeirão Preto, Ribeirão Preto, SP, Brazil.
Rodrigues
G G R
GG
Bigal
M E
ME
Speciali
J G
JG
D000368:Aged; D052160:Benzothiazoles / Q000008:administration & dosage*; D002054:Burning Mouth Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D009061:Mouth Mucosa / Q000187:drug effects* / Q000294:innervation / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D000077487:Pramipexole; D011446:Prospective Studies; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000378:metabolism; D012148:Restless Legs Syndrome / Q000188:drug therapy / Q000503:physiopathology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D016896:Treatment Outcome
D052160:Benzothiazoles; D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D000077487:Pramipexole; D004298:Dopamine